Conventional lipid panels report LDL-C — the mass of cholesterol carried inside low-density lipoprotein particles. ApoB, by contrast, counts the particles themselves. Every atherogenic lipoprotein (LDL, VLDL, IDL, Lp(a), chylomicron remnants) carries exactly one molecule of apolipoprotein B, so measuring ApoB measures the number of particles that can actually penetrate the arterial wall and seed plaque.

In most people LDL-C and ApoB tell a similar story. The trouble starts in the people who matter most for prevention: those with type 2 diabetes, metabolic syndrome, central adiposity, or high triglycerides. Their LDL particles tend to be small and cholesterol-poor, so they carry many particles for a given LDL-C mass — a phenomenon Allan Sniderman has spent two decades documenting as 'discordance.' For these people, LDL-C systematically underestimates risk while ApoB tracks it.

This is why the 2019 ESC/EAS dyslipidaemia guidelines elevated ApoB to a Class I recommendation for risk assessment in people with high triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL-C — and why the 2025 ESC/EAS focused update reinforced ApoB as the preferred marker in those settings. The US ACC/AHA 2018 cholesterol guideline takes a more conservative posture but acknowledges ApoB and non-HDL-C as alternatives.

A note on evidence strength: the case for ApoB outperforming LDL-C rests on large observational cohorts (UK Biobank, Copenhagen General Population Study) and Mendelian randomization analyses. We do not yet have a randomized trial that directly compares 'treat to ApoB' against 'treat to LDL-C' for hard cardiovascular endpoints. The mechanistic and epidemiological case is strong, but it is not RCT-grade.

Lipoprotein(a) is an LDL-like particle with an extra protein, apolipoprotein(a), covalently attached. Its plasma concentration is set ~70–90% by your LPA gene and is established by your mid-twenties. Diet, exercise, statins, and most lifestyle levers barely move it. About one in five people of European ancestry carries levels associated with elevated atherosclerotic and aortic-valve risk, and prevalence is higher in people of African ancestry.

The Erqou et al. 2009 JAMA meta-analysis of 36 prospective studies established the independent, continuous association between Lp(a) and coronary heart disease. The Tsimikas 2017 'Test in Context' review in JACC consolidated the case for Lp(a) as a causal, independent risk factor. The Kronenberg-led EAS 2022 Consensus Statement formalized the contemporary view: Lp(a) should be measured at least once in adulthood in every adult, as part of comprehensive cardiovascular risk assessment.

Managing expectations matters here. As of 2026 there is no approved drug specifically for lowering Lp(a). Three large outcome trials are running: Lp(a) HORIZON (pelacarsen, antisense oligonucleotide, Ionis/Novartis), OCEAN(a)-Outcomes (olpasiran, siRNA, Amgen), and ACCLAIM-Lp(a) (lepodisiran, siRNA, Eli Lilly). None has reported primary cardiovascular endpoints at the time of writing, and none is approved by the EMA or the FDA. PCSK9 inhibitors modestly reduce Lp(a) (roughly 25–30% in FOURIER and ODYSSEY OUTCOMES) as a side effect of their LDL-C lowering, but they are not licensed for Lp(a) per se.

What does change when you know your Lp(a) is high is the rest of your risk picture. Guidelines and clinical practice converge on treating other modifiable risk factors more aggressively — blood pressure, ApoB-containing lipoproteins, smoking, glycaemic control — to compensate for the unmodifiable Lp(a) burden. That recalibration is the practical value of the test.

Lab reports vary in units and reference ranges, which is half the confusion. ApoB is reported in g/L or mg/dL. Lp(a) is reported either in mass units (mg/dL) or — preferred by ESC/EAS — in molar units (nmol/L), and the two are not interchangeable because Lp(a) isoforms differ in size. Always check which unit your report uses before comparing yourself to a number you read online.

For ApoB, the 2019 ESC/EAS guideline frames goals by overall cardiovascular risk category rather than by a one-size threshold. People at very high risk are expected to reach much lower ApoB than people at low risk; the same logic applies to LDL-C. The 2025 focused update kept this risk-stratified approach. A single number on a screen, divorced from your age, blood pressure, smoking status, family history, and other risk factors, does not tell you what your target should be. That is a conversation for your Kardiologin or Hausärztin.

For Lp(a), the EAS 2022 consensus describes risk as continuous: there is no clean cut-off where danger begins. Many labs flag values above roughly 50 mg/dL or 105–125 nmol/L as elevated (isoform-correction varies between methods; the 2025 ESC/EAS Focused Update on dyslipidaemia uses 105 nmol/L specifically), but the EAS document explicitly describes the relationship as graded — very high values (e.g. above 180 mg/dL or 430 nmol/L) confer roughly double the lifetime cardiovascular risk of the general population, similar in magnitude to heterozygous familial hypercholesterolaemia. Again, your number is one input among many.

Two practical things to keep in mind. First, both markers should ideally be interpreted in the context of a full lipid panel, hs-CRP, blood pressure, glucose/HbA1c, and a credible family history. Second, primary prevention (you have never had an event) and secondary prevention (you have) follow different treatment logics. The same Lp(a) value carries different implications in those two settings.

The German statutory Check-up 35 (Gesundheitsuntersuchung), which Kassenpatienten can claim every three years from age 35, includes a basic lipid panel: total cholesterol, HDL-C, LDL-C, and triglycerides. ApoB and Lp(a) are not part of this baseline. Neither is hs-CRP, fasting insulin, or HbA1c outside specific clinical indications. Your Hausärztin is doing what the GKV-defined check-up specifies — not what an interested longevity-conscious patient would necessarily order.

This is not a German peculiarity born of negligence. Most national primary-care systems anchor on LDL-C because LDL-C is what the bulk of the trial evidence and clinical risk scores were built on. ApoB and Lp(a) entered guidelines as risk-refiners more recently, and primary-care reimbursement schedules trail the guidelines by years. The DGFF (Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen, also known as Lipid-Liga) and the Lipid-Liga's patient guidance have been actively pushing for broader Lp(a) testing, but coverage decisions sit with the G-BA, not the medical societies.

For most patients the practical answer is: ApoB and Lp(a) are typically IGeL (Individuelle Gesundheitsleistung) — self-pay add-ons — unless you have an established clinical indication. Indications that may move them into Kassen-paid territory include known coronary artery disease, premature familial cardiovascular disease, statin intolerance, very high LDL-C raising suspicion of familial hypercholesterolaemia, or recurrent events despite well-controlled LDL-C. Bring documented family history with you — it is genuinely the most useful single thing you can give a GP making this decision.

If your Hausärztin declines to order them, that is normal and not an insult to her medical judgement. The realistic options are: ask her to add them as an IGeL/Selbstzahler request to your next lab draw, or use a Selbstzahler service that orders from a major lab like Synlab, Limbach, or Sonic on your behalf. Both routes use the same labs.

In Germany, ApoB and Lp(a) are routinely available through the three large laboratory networks — Synlab, Limbach, and Sonic Healthcare (Bioscientia, Medizinische Labore Volkmann, MVZ Augsburg, etc.). Either your Hausärztin orders them and bills you privately under GOÄ (Gebührenordnung für Ärzte), or you use a Selbstzahler service that ships your blood to one of those same labs. As a rough orientation, Lp(a) typically runs in the range of approximately 20–40 EUR and ApoB approximately 10–25 EUR per marker as Selbstzahler, plus venepuncture and a service fee. The exact figure depends on lab, region, and whether the markers are part of a wider panel. Verify before ordering — prices listed online drift and are sometimes promotional.

In Austria, the Wahlarzt model is the most common route. A Wahlarzt or Wahlarzt-Labor will draw your blood, bill you privately, and you submit the invoice to your Krankenkasse for partial reimbursement under the standard rules — typically you get back roughly 80% of the equivalent Kassen tariff, which for niche markers like Lp(a) can be considerably less than what you paid. ÖGK does not generally reimburse Lp(a) testing outside specific clinical indications.

In Switzerland the picture is the simplest in some ways and the most expensive in others. Without a clear medical indication, both ApoB and Lp(a) are almost always self-paid out of your annual Franchise plus the Selbstbehalt. Lab prices are higher than in Germany or Austria — a rough range for combined ApoB and Lp(a) is comparable to or above 100 CHF — but you do not navigate an IGeL conversation. If your Hausarzt or Kardiologe believes there is an indication, the test goes through OKP and you carry the standard cost-sharing.

Across all three countries, a few practical tips help. Fast for 10–12 hours if your panel includes triglycerides and your doctor agrees; ApoB and Lp(a) themselves are not strongly fasting-dependent, but the rest of the panel may be. Sit calmly for ten minutes before the draw. Avoid an acute illness or recent vaccination, which can transiently shift lipids and especially Lp(a). And ask the lab in advance which Lp(a) unit (mg/dL or nmol/L) and which assay (isoform-insensitive is preferred) they use.

First and most important: this guide does not prescribe a protocol. If your ApoB or Lp(a) comes back elevated, the right next step is a conversation with your Hausärztin or, better, a Kardiologin or lipidology-trained Wahlärztin/Wahlarzt. The decision tree branches heavily on your age, your other risk factors, your family history, and whether you are in primary or secondary prevention. There is no single right answer.

What helps that conversation be productive: bring your full lipid panel, a documented family history of cardiovascular events (with ages), your blood pressure trend, glucose or HbA1c if available, your smoking status, and a list of medications. Ask explicit questions rather than expecting your doctor to volunteer them. Useful questions include: 'Where does my overall ESC SCORE2 risk land?' 'Does my Lp(a) push me into a higher-risk band that changes how aggressively we treat my LDL-C and blood pressure?' 'Is a coronary calcium score (CAC) reasonable for me as a tiebreaker?' 'Are there indications for lipid-lowering therapy that I meet, given my full picture?'

About lifestyle: please read this carefully. The Mediterranean dietary pattern, regular aerobic and resistance exercise, not smoking, sleeping enough, and keeping central adiposity in check all improve cardiovascular outcomes and modestly improve ApoB-containing lipoproteins. They will not normalize a genetically high Lp(a). Treating lifestyle as 'the Lp(a) protocol' is exactly the kind of magical thinking this guide is trying to avoid. Lifestyle is worth doing on its own merits, regardless of your Lp(a). Frame it that way.

Finally, on the longevity-medicine framing that floats around social media: it is genuinely useful for some people to know their ApoB and Lp(a) earlier rather than later, especially those with a strong family history of premature cardiovascular events. It is not useful for an asymptomatic healthy person with no family history to spiral into anxiety over a single elevated number. Test if you can act on the result with a clinician you trust. Otherwise, the test is information you cannot use.